COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01299012
Recruitment Status : Completed
First Posted : February 18, 2011
Last Update Posted : February 10, 2017
Information provided by (Responsible Party):
Paresh Dandona, Kaleida Health

Brief Summary:
Evaluating the use of Liraglutide in patients with Type 1 Diabetes.

Condition or disease Intervention/treatment
Type 1 Diabetes Mellitus Drug: Liraglutide

Detailed Description:

This investigation will be a retrospective chart review of in type 1 diabetics who have been treated with liraglutide. The study will be conducted at Diabetes-Endocrinology Center of WNY at Millard Fillmore Hospital, affiliated to the State University of New York at Buffalo.

Study Population: 40 patients with type 1 diabetes on treatment with either continuous subcutaneous insulin infusion (CSII; also known as insulin pump) or multiple (four or more) injections of insulin per day on continuous glucose monitoring system (CGMS) will be included in the study. These patients with type 1 diabetes have been treated with liraglutide in addition to insulin. The investigators would retrospectively review their charts to evaluate decreases in fasting, postprandial and the overall mean glucose concentrations.

The investigators will compare the mean fasting, the mean weekly glucose and the standard deviation of weekly blood glucose concentrations as recorded by continuous glucose monitoring prior to and following one week and 12 weeks of treatment with liraglutide daily. In addition, the investigators will compare the time spent at glucose concentrations >150 and 200mg/dl and <70 and <40 mg/dl. HbA1c levels before and after 12 weeks of treatment with liraglutide daily will be compared.

Layout table for study information
Study Type : Observational
Actual Enrollment : 30 participants
Observational Model: Other
Time Perspective: Retrospective
Official Title: Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus, a Retrospective Chart Review
Study Start Date : October 2010
Actual Primary Completion Date : February 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1
Drug Information available for: Liraglutide

Intervention Details:
  • Drug: Liraglutide
    Liraglutide s/c 0.6mg once daily.
    Other Name: Victoza

Primary Outcome Measures :
  1. Improved Blood Glucose comtrol in Type 1 Diabetes Patients with Liraglutide [ Time Frame: 20 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Type 1 Diabetes Mellitus

Inclusion Criteria:

  • Type 1 Diabetes Mellitus

Exclusion Criteria:

  • Type 2 Diabetes Mellitus

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01299012

Sponsors and Collaborators
University at Buffalo
Layout table for investigator information
Principal Investigator: Paresh Dandona University at Buffalo
Layout table for additonal information
Responsible Party: Paresh Dandona, MD, Kaleida Health Identifier: NCT01299012    
Other Study ID Numbers: 1954
First Posted: February 18, 2011    Key Record Dates
Last Update Posted: February 10, 2017
Last Verified: February 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists